Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positive Regulator Molecules

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Inhibition of CDK Activity

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.

Cancer discovery·2026

Same author

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Transcriptional cyclin-dependent kinases Cdk8 and Cdk19 are required for normal macrophage differentiation.

Cell cycle (Georgetown, Tex.)·2025

Same author

PC4: A new regulator of cyclin D1 transcript levels.

The Journal of cell biology·2024

Same author

Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1.

Science (New York, N.Y.)·2023

Search research articles

Related Experiment Video

Updated: May 9, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Targeting Transcriptional Cyclin-Dependent Kinases in Cancer.

Aleksandra Kolodziejczyk^1,2, Piotr Sicinski^1,2

¹Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Molecular Cancer Therapeutics

|July 15, 2025

Summary

Transcriptional cyclin-dependent kinases (tCDKs) are crucial for cancer growth. Inhibiting tCDKs shows promise in preclinical cancer models by selectively targeting cancer cells, offering a new therapeutic avenue.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TE^deff) in Cancers

Published on: September 26, 2019

Related Experiment Videos

Last Updated: May 9, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TE^deff) in Cancers

Published on: September 26, 2019

Area of Science:

Molecular Biology
Cancer Biology
Pharmacology

Background:

Cyclin-dependent kinases (CDKs) are vital for cell cycle and transcription.
Dysregulated CDKs are common in cancer.
Transcriptional CDKs (tCDKs) are emerging as key therapeutic targets.

Purpose of the Study:

To explore the therapeutic potential of targeting transcriptional CDKs (tCDKs) in cancer treatment.
To highlight the role of tCDKs in tumor growth and survival.
To discuss challenges and future directions in tCDK inhibitor development.

Main Methods:

Review of preclinical studies on tCDK inhibitors.
Analysis of the mechanisms underlying tCDK selectivity in cancer cells.
Exploration of emerging strategies like targeted protein degradation.

Main Results:

tCDK inhibitors demonstrate efficacy in preclinical cancer models.
Selectivity is observed due to cancer cells' heightened dependence on transcription (oncogene addiction).
tCDKs regulate critical processes like RNA polymerase activation and transcriptional elongation.

Conclusions:

Targeting tCDKs is a promising strategy for cancers with high transcriptional activity.
Challenges include inhibitor specificity and understanding broader biological impacts.
Further research and novel strategies like targeted degradation are needed for clinical translation.